ELAB on Nasdaq

PMGC Holdings Inc.

PMGC Holdings Inc. is an American pharmaceutical preparations company based in Newport Beach.1 Its shares trade on Nasdaq under the symbol ELAB.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Ernexa Therapeutics Inc., VACCINEX, INC. or Yarrow Bioscience, Inc., or pick any stock.

  • TickerELAB on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNewport Beach, California1
  • Incorporated inDE2
  • Business address120 Newport Center Drive, Newport Beach, Ca 926602
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Pacific Sun Packaging, Inc. (“Pacific Sun Packaging” or “Pacific Sun”) is a specialty packaging provider focused on high-precision, component-level packaging solutions for the electronics and information technology (“IT”) hardware industries. The company designs and supplies custom-engineered protective packaging for delicate components such as central processing units (“CPUs”), memory modules (Dual In-line Memory Modules (“DIMMs”) and Small Outline Dual Inline Memory Modules (“SO-DIMMs”), solid state drives (“SSDs”), hard disk drives (“HDDs”), and fiber-optic transceivers, serving customers across the semiconductor, data center, and networking equipment supply chains.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

31.4%Gross margin4
-1313.0%Net margin4
-98.9%Return on equity4
-$6.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue69¢$404.8K
  • Research and development25¢$147.0K
  • Other costs1¢$7.3K
  • Income tax5¢$31.0K

Out of $590.1K in revenue.4 The company lost money this year.

Financial statements

Revenue54$590.1K in 2025−23% since 2022
0$500.0K$1.0M$1.5M$2.0M2022: $766.3K$766.3K20222023: $1.7M$1.7M2023+123%2025: $590.1K$590.1K2025−66%
Gross profit54$185.3K in 2025−59% since 2022
0$500.0K$1.0M$1.5M2022: $447.3K$447.3K20222023: $1.1M$1.1M2023+154%2025: $185.3K$185.3K2025−84%
Net income564-$7.7M in 2025+330% since 2022
-$8.0M-$6.0M-$4.0M-$2.0M02022: -$1.8M-$1.8M20222023: -$4.3M-$4.3M2023+139%2024: -$6.2M-$6.2M2024+45%2025: -$7.7M-$7.7M2025+24%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue$590.1K
Total revenue$590.1K
Cost of Goods Sold$404.8K
Gross margin$185.3K
Bad debt expense$55.4K
Depreciation and amortization$96.1K$546
Marketing and promotion$200.9K$292.5K
Consulting fees$1.8M$1.4M
Office and administrative$2.2M$1.1M
Professional fees$1.4M$563.2K
Investor relations$253.3K$208.3K
Research and development$147.0K$104.7K
Repairs and maintenance$717.7K
Foreign exchange (gain) loss$5.2K$5.8K
Travel and entertainment$160.4K$28.6K
Total operating expenses$7.1M$3.7M
Finance cost on ELOC-$289.5K
Change in fair value of derivative liabilities$214.2K$369.2K
Gain on the termination of intangible assets$129.6K
Loss on disposal of PP&E-$32.4K
Gain on extinguishment of related-party debt$31.3K
Interest income$118.0K$12.9K
Interest expense-$257.6K-$735.2K
Impairment on prepaid expense-$500.0K
Dividend income$15.6K
Other Income$33.1K
Realized gain (loss) on investments-$113.9K
Unrealized gain (loss) on investments-$216.0K
Loss from continuing operations before tax-$7.7M-$4.0M
Deferred tax expense-$31.0K
Net loss from continuing operations-$7.8M-$4.0M
Income (loss) from discontinued operations$32.9K-$2.2M
Total net loss-$7.7M-$6.2M
Currency translation adjustment-$2.0K-$539
Total comprehensive loss-$7.7M-$6.2M
Continuing operations (in Dollars per share)-$382-$4.2K
Continuing operations, diluted (in Dollars per share)-$382-$4.2K
Discontinued operations (in Dollars per share)$2-$2.4K
Discontinued operations, diluted (in Dollars per share)$2-$2.4K
Weighted average shares outstanding (in Shares)20.4K shares947 shares

Compare PMGC Holdings Inc. with another company

Corporate structure

PMGC Holdings Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PMGC Holdings Inc.

  • NorthStrive Acquisition Corp I. Filed SCHEDULE 13D on PMGC Holdings Inc., latest Sep 29, 2026
  • Graydon Bensler Filed SCHEDULE 13D on PMGC Holdings Inc., latest Jun 3, 2026 (2 filings since Mar 28, 2025)
  • Lichti Braeden Filed SCHEDULE 13D/A on PMGC Holdings Inc., latest Jun 3, 2026 (4 filings since Feb 21, 2024)
  • Streeterville Capital LLC Filed SCHEDULE 13G/A on PMGC Holdings Inc., latest May 27, 2026 (3 filings since Sep 29, 2025)
  • L1 Capital Global Opportunities Master Fund, Ltd. Filed SCHEDULE 13G/A on PMGC Holdings Inc., latest Feb 17, 2026 (3 filings since Oct 1, 2024)
  • S.H.N. Financial Investments Ltd. Filed SCHEDULE 13G/A on PMGC Holdings Inc., latest May 15, 2025 (3 filings since Oct 2, 2024)
  • BIGGER CAPITAL FUND L P Filed SCHEDULE 13G/A on PMGC Holdings Inc., latest Apr 16, 2025 (2 filings since Mar 24, 2025)
  • Altium Capital Management LLC Filed SCHEDULE 13G/A on PMGC Holdings Inc., latest Feb 14, 2025 (2 filings since Sep 26, 2024)
  • Anson Funds Management LP Filed SCHEDULE 13G/A on PMGC Holdings Inc., latest Feb 14, 2025 (2 filings since Nov 14, 2024)
  • Santorio Biomedical, LLC Filed SCHEDULE 13G on PMGC Holdings Inc., latest Aug 16, 2024
  • MOA LIFE PLUS CO. LTD. Filed SC 13G on PMGC Holdings Inc., latest May 31, 2024
  • Hatem Abou-Sayed Filed SC 13G on PMGC Holdings Inc., latest Feb 14, 2024
  • PMGC Holdings Inc. Newport Beach, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PMGC Holdings Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$939.1K4 Dec 31, 2025$2.6K4 Dec 31, 2024+36003.5%
Accumulated depreciation$53.5K4 Dec 31, 2025$1.5K4 Dec 31, 2024+3435.8%
Property and equipment, net$885.5K4 Dec 31, 2025$1.1K4 Dec 31, 2024+81364.6%
Operating-lease assets (leased space)$1.2M4 Dec 31, 2025$206.6K5 Dec 31, 2023+501.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.0M6 Dec 31, 2024$3.3M6 Dec 31, 2023+19.8%
Marketable securities, current$572.1K4 Dec 31, 2025
Marketable securities, non-current$139.1K4 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$977.8K4 Dec 31, 2025
Intangible assets, net (excluding goodwill)$2.9M4 Dec 31, 2025$2.8M4 Dec 31, 2024+3.2%
Finite-lived intangibles, gross$2.9M4 Dec 31, 2025$2.9M4 Dec 31, 2024+1.7%
Accumulated amortization$41.5K4 Dec 31, 2025$82.6K4 Dec 31, 2024−49.7%
Finite-lived intangibles, net$135.4K4 Dec 31, 2025

Inventory

ItemLatestA year beforeChange
Inventory, total$95.1K4 Dec 31, 2025$495.7K5 Dec 31, 2023−80.8%
Raw materials$10.0K4 Dec 31, 2025
Finished goods$85.1K4 Dec 31, 2025

Properties, in its own words

Our principal executive office is located at 120 Newport Center Drive, Newport Beach, CA 92660. The office has 1,650 square feet, and the lease is on a month-to-month basis. The monthly rent is $9,273.50.

The following table sets forth the leases term and monthly rent:

The rest of Item 2

Lease Term · Address · Space (square feet) · Average Monthly Rent

Month to Month · 120 Newport Center Drive, Newport Beach, CA 92660 · 1,650 · 9,273.50

Some members of our management work outside of these premises in office space that we do not rent.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led PMGC Holdings Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jordan R. Plews2024
  2. Graydon Bensler2025–now

Chief financial officer

  1. Graydon Bensler2024–now
2025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerBrenda Buechler named Mar 17, 2023 to Sep 22, 202320
  • DirectorJulie Daley named Sep 11, 2023 to Sep 22, 202320
  • DirectorYi Guo named Oct 1, 2021 to Dec 10, 202121
  • PromoterBraeden Lichti named Oct 1, 2021 to Sep 22, 202320

Former names

  • Elevai Labs Inc.Dec 10, 2021 to Nov 27, 20242
  • Reactive Medical Labs Inc.Oct 1, 2021 to Oct 14, 20212

Timeline

  1. Sep 18, 20268-K Regulation FD disclosure22
  2. Sep 2, 20268-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed23
  3. Aug 27, 20268-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed24
  4. Jul 9, 20268-K Entered a material agreement25
  5. Jul 7, 20268-K Entered a material agreement26
  6. Jul 1, 20268-K Regulation FD disclosure27
  7. Jun 8, 20268-K Bylaws or fiscal year changed; Shareholder vote28
  8. Jun 5, 20268-K Entered a material agreement29
  9. May 13, 20268-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure30
  10. Apr 28, 20268-K Regulation FD disclosure31
  11. Apr 23, 20268-K Regulation FD disclosure32
  12. Apr 21, 20268-K Regulation FD disclosure33
  13. Mar 28, 2025New chief executive Graydon Bensler becomes CEO9
  14. Jan 18, 2024New chief executive Jordan R. Plews becomes CEO10

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202634

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

269 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 100 major events, 28 insider forms, 28 large holders, 11 private raises, 90 other. The latest 20:

  1. Sep 29, 2026SCHEDULE 13D EDGAR
  2. Sep 18, 20268-K CURRENT REPORT EDGAR
  3. Sep 2, 20268-K CURRENT REPORT EDGAR
  4. Aug 27, 20268-K CURRENT REPORT EDGAR
  5. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  6. Jul 9, 20268-K CURRENT REPORT EDGAR
  7. Jul 7, 20268-K CURRENT REPORT EDGAR
  8. Jul 1, 20268-K CURRENT REPORT EDGAR
  9. Jun 8, 20268-K CURRENT REPORT EDGAR
  10. Jun 5, 20268-K CURRENT REPORT EDGAR
  11. Jun 3, 2026SCHEDULE 13D/A EDGAR
  12. Jun 3, 2026SCHEDULE 13D EDGAR
  13. Jun 3, 20264 EDGAR
  14. Jun 3, 20264 EDGAR
  15. Jun 2, 20264 EDGAR
  16. Jun 2, 20264 EDGAR
  17. Jun 2, 20264 EDGAR
  18. May 27, 2026SCHEDULE 13G/A EDGAR
  19. May 15, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  20. May 15, 202610-Q QUARTERLY REPORT EDGAR

The 269 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Graydon Bensler34$262.0K$697.8K50
2024Non-EmployeeNon-Executive Chief Executive Officer, Chief Financial Officer and Director$196.3K$391.3K50
2024Former DirectorChief Executive Officer, and President$228.3K$253.3K50
2024Former Chief Marketing Officer$98.5K$118.5K50
2024Former Commercial Officer$92.2K$112.2K50

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 8, 2023Raised $249,996 in a private offering of equity Form D: $549,990 offered in all Form D
  2. Mar 14, 2023Raised $463,589 in a private offering of equity Form D: $1.6 million offered in all Form D
  3. Mar 3, 2023Raised $750,000 in a private offering of equity Form D: $1.5 million offered in all Form D
  4. Jul 15, 2022Raised $3 million in a private offering of securities Form D: $4.3 million offered in all Form D
  5. Aug 24, 2021Raised $1.1 million in a private offering of equity Form D: $2 million offered in all Form D
  6. Jun 24, 2020Raised $138,999 in a private offering of securities Form D: 7 investors so far Form D

SEC filer profile

How PMGC Holdings Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPMGC Holdings Inc.1
  • CIK0001840563
  • Employer ID (EIN)33-23825473
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address120 Newport Center Drive, Newport Beach, CA 926601
  • Phone888-445-48861
  • Shares outstanding8,095,793 as of Aug 14, 20268
  • Public float$101.0M as of Jun 30, 20253
  • AuditorHTL International, LLC, Houston PCAOB ID 7000; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceOct 1, 20211
  • Filings269 in all: 8-K (98), 3 (14), 10-Q (9), CORRESP (9), SC 13G (9), 4 (8), DEF 14C (8), PRE 14C (8)1
    All 38 form types

    S-1/A (8), SCHEDULE 13G/A (8), UPLOAD (8), 3/A (6), 424B5 (6), D (6), EFFECT (6), D/A (5), S-1 (5), SCHEDULE 13D (4), SCHEDULE 13G (4), 10-K (3), 424B3 (3), DEF 14A (3), DEFR14C (3), DRS/A (3), DRSLTR (3), PRE 14A (3), 424B4 (2), 8-K/A (2), DRS (2), PRER14C (2), SC TO-I/A (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), S-3 (1), SC 13D (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) May 15, 2026
    Latest 8-K (8-K) Sep 18, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareELABThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks PMGC Holdings Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 70 risks under these headings, as written.3

  • RISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL STRUCTURE
  • Our financial statements have been prepared on a going-concern basis and our continued operations are in doubt.
  • We have a history of net losses, and we may not be able to achieve or maintain profitability in the future.
  • Our operating cash consumption significantly exceeds our revenue, and we may not be able to fund our operations without continued access to the capital markets.
  • We will need additional capital to conduct our operations and develop our products and businesses, and our ability to obtain the necessary funding is uncertain.
  • Our existing equity purchase facility may result in substantial dilution to our existing stockholders and may place downward pressure on the price of our Common Stock.
  • Our equity interests in our key subsidiaries and the assets of those subsidiaries are pledged as collateral under our equity purchase facility with Streeterville, and a default on our obligations pursuant to such facility could result in the loss of our operating businesses.
  • We have conducted multiple reverse stock splits in a short period of time, which may adversely affect the market price of our Common Stock and investor confidence.
  • If we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize our products and grow our businesses.
  • We may need, but be unable, to obtain additional funding on satisfactory terms, which could dilute our stockholders or impose burdensome financial restrictions on our business.
  • We may be unable to realize the expected value from the divestiture of our Elevai Skincare business, including earn-out payments.
  • Changes in tax laws or regulations could adversely affect our business and financial results.
The other 59 risks
  • RISKS RELATED TO OUR HOLDING COMPANY STRUCTURE AND ACQUISITION STRATEGY
  • Our diversified holding company structure may make our business more complex and difficult to manage.
  • Our results depend on our ability to allocate capital effectively across our subsidiaries and investments.
  • We may not realize anticipated benefits from operating as a platform of multiple businesses.
  • Our growth strategy depends on acquisitions, which involve significant risks and uncertainties.
  • Potential business combinations could require significant management attention, prove difficult to integrate, and adversely affect our operating results.
  • The purchase price allocations for our acquisitions may be preliminary and subject to adjustment, which could materially affect our reported financial results.
  • We have recorded goodwill on our consolidated balance sheet that may be subject to impairment, which could adversely affect our financial results.
  • Earn-out and contingent consideration arrangements may result in disputes or financial obligations that adversely affect our results.
  • We depend on the founders and key employees of our acquired businesses, and their departure could adversely affect the performance of those businesses.
  • RISKS RELATED TO OUR OPERATING SUBSIDIARIES
  • Risks Related to Northstrive Biosciences Inc. (Biotechnology)
  • Our biotechnology subsidiary, Northstrive Biosciences, is at an early stage of product development, and we may not develop products that can be successfully commercialized.
  • Because our future commercial success with respect to our Licensed Products (as defined below) depends on gaining regulatory approval, we cannot generate therapeutic revenue without obtaining such approvals.
  • The development and acquisition of therapeutic product candidates could expose us to significant legal and regulatory risks.
  • If we are unable to successfully complete preclinical testing and clinical trials of the Licensed Products or experience significant delays in doing so, our business will be materially harmed.
  • The Licensed Products may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
  • We license from a third party the rights to our therapeutic product candidates and are therefore subject to the risk that we lose this license after investing substantial resources.
  • Our products under development could be rendered obsolete by technological or other medical advances.
  • Since we rely on third parties to conduct, supervise and monitor pre-clinical and clinical trials, their failure to perform satisfactorily may materially harm our business.
  • Because third parties may be developing competitive products without our knowledge, we may later learn that competitive products are superior to the Licensed Products.
  • Our therapeutic products may be expensive to manufacture, and they may not be profitable if we are unable to control the costs to manufacture them.
  • Risks Related to Pacific Sun Packaging, Inc. (Specialty Packaging)
  • Pacific Sun Packaging operates in a competitive industry and may face pricing pressure from larger competitors.
  • Pacific Sun Packaging’s revenue depends on the IT hardware industry, which is subject to cyclical and secular changes.
  • Pacific Sun Packaging is dependent on a limited number of suppliers for raw materials and components.
  • Risks Related to AGA Precision Systems LLC (Precision Manufacturing)
  • AGA Precision Systems operates in industries subject to stringent regulatory requirements, including International Traffic in Arms Regulations.
  • Maintaining and renewing industry certifications, including AS9100, is critical to AGA’s ability to serve its customers.
  • AGA Precision Systems has incurred, and may continue to incur, significant repair and maintenance costs, and the condition of its equipment may require ongoing capital investment.
  • AGA Precision Systems has historically operated without a formal sales and marketing function, which may limit its growth.
  • Risks Related to All Operating Subsidiaries
  • Our operations across multiple industries expose us to diverse and potentially conflicting market risks.
  • We may be subject to liability for workplace safety and employment-related claims across our operating subsidiaries.
  • Our insurance coverage may be inadequate to protect us against all potential losses and liabilities.
  • A portion of our revenue may be derived from a limited number of customers.
  • Disruptions in supply chains or manufacturing operations could adversely affect our business.
  • A disruption in our operations could have an adverse effect on our business.
  • To sustain our growth, we will need to increase the size of our organization, and we may encounter difficulties managing growth across multiple subsidiaries.
  • RISKS RELATED TO OUR INVESTMENT ACTIVITIES (PMGC CAPITAL)
  • PMGC Capital LLC may be deemed an “investment company” under the Investment Company Act of 1940, which could impose significant regulatory burdens.
  • PMGC Capital’s investment activities subject us to market risk, and we may incur losses on our investment portfolio.
  • RISKS RELATED TO REGULATORY, LEGAL AND INTELLECTUAL PROPERTY MATTERS
  • We may become subject to litigation, regulatory proceedings, or governmental investigations that could be costly and time-consuming.
  • We are subject to anti-corruption, anti-bribery, and similar laws, and non-compliance could expose us to significant penalties.
  • Changes in U.S. trade policy, tariffs, and international relations could adversely affect our supply chain and cost structure.
  • If we fail to protect or enforce our intellectual property, others could compete against us more directly and we may not be able to compete effectively in our market.
  • Certain of our technology may not be subject to protection through patents, which leaves us vulnerable to theft of our technology.
  • We may not be able to protect our proprietary technology, which may harm our ability to operate profitably.
  • Patents held by other persons may result in infringement claims against us that are costly to defend and which may limit our ability to use disputed technologies.
  • If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our target markets.
  • If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.
  • We may need to license additional intellectual property from third parties in the future, and such licenses may not be available on commercially reasonable terms.
  • A recall or suspension of sale of our products, or the discovery of serious safety issues, could have a significant negative impact on us.
  • Regulations governing our products could harm our business.
  • Government regulations relating to marketing and advertising may restrict, inhibit or delay our ability to sell our products.
  • We may incur product liability claims that could harm our business, and past product liability claims relating to our previously divested Elevai Skincare products could still adversely affect our business.
  • We may not have sufficient product liability insurance, which may leave us vulnerable to future claims we will be unable to satisfy.
  • Our employees, independent contractors, consultants, distributors, vendors and strategic partners may engage in misconduct or improper activities.
  • If we, or our third-party manufacturers fail to comply with environmental laws and regulations, we could become subject to fines or penalties.
  • If our third-party suppliers, logistics providers, and manufacturers do not comply with ethical business practices or applicable laws, our reputation and business could be harmed.
  • The divestiture of our Elevai Skincare business could negatively impact our operations and strategic positioning.
  • RISKS RELATED TO OUR MANAGEMENT AND GOVERNANCE
  • Our corporate governance documents and Nevada law may have anti-takeover effects that could discourage, delay, or prevent a change in control.
  • If we lose key personnel or are unable to attract and retain qualified personnel, we may be unable to execute our business plan.
  • Graydon Bensler serves as both our Chief Executive Officer and Chief Financial Officer, which presents governance risks and limitations.
  • Significant related-party transactions with entities controlled by our executive officers and directors may present conflicts of interest.
  • We may be unable to accurately forecast revenue and appropriately plan our expenses.

Legal proceedings

As of the date of this Annual Report, there are no active legal proceedings pending or threatened against the Company. However, from time to time, we may be subject to various legal claims and proceedings that arise from the normal course of business activities, including, third party intellectual property infringement claims against us in the form of letters and other forms of communication. Litigation or any other legal or administrative proceeding, regardless of the outcome, could result in substantial cost, diversion of our resources, including management’s time and attention, and, depending on the nature of the claims, reputational harm. In addition, if any litigation results in an unfavorable outcome, there exists the possibility of a material adverse impact on our results of operations, prospects, cash flows, financial position and brand.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50